Insider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires $39,800.00 in Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock in a transaction dated Wednesday, July 8th. The stock was acquired at an average price of $1.99 per share, for a total transaction of $39,800.00. Following the completion of the transaction, the director owned 436,904 shares in the company, valued at approximately $869,438.96. The trade was a 4.80% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Robert Jr. Baltera also recently made the following trade(s):

• On Thursday, July 9th, Robert Jr. Baltera acquired 25,000 shares of Palisade Bio stock. The shares were acquired at an average cost of $1.96 per share, with a total value of $49,000.00.
• On Tuesday, July 7th, Robert Jr. Baltera acquired 30,000 shares of Palisade Bio stock. The shares were acquired at an average price of $2.03 per share, for a total transaction of $60,900.00.
• On Monday, July 6th, Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $41,000.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were bought at an average cost of $1.98 per share, with a total value of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The stock was bought at an average cost of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

NASDAQ:PALI opened at $1.96 on Monday. The firm has a market capitalization of $340.22 million, a P/E ratio of -1.94 and a beta of 1.50. The business has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $1.92. Palisade Bio, Inc. has a 12-month low of $0.53 and a 12-month high of $2.85.

Palisade Bio (NASDAQ:PALI) last issued its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Research analysts anticipate that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on PALI shares. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a research report on Tuesday, June 30th. Wolfe Research assumed coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Wall Street Zen lowered shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Monday. Oppenheimer set a $7.00 price target on Palisade Bio in a report on Tuesday, June 30th. Finally, Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Palisade Bio has an average rating of “Buy” and an average price target of $8.83.

Institutional Investors Weigh In On Palisade Bio

Several institutional investors have recently bought and sold shares of PALI. XTX Topco Ltd lifted its holdings in Palisade Bio by 53.8% in the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after purchasing an additional 7,584 shares during the period. Cetera Investment Advisers bought a new stake in shares of Palisade Bio during the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new stake in shares of Palisade Bio in the 4th quarter worth approximately $28,000. Finally, Atom Investors LP acquired a new stake in shares of Palisade Bio in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.